BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15041924)

  • 1. [Prostate cancer and prostate specific antigen screening].
    Camici M
    Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
    J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
    Dorr VJ; Williamson SK; Stephens RL
    Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer. When to offer screening in the primary care setting.
    Gambert SR
    Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to use PSA to screen for prostate cancer.
    Little B; Young M
    Int J Clin Pract; 2003; 57(1):40-2. PubMed ID: 12587941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostatic specific antigen in practice in 1997].
    Salomon L; Colombel M; Patard JJ; Chopin D; Abbou CC
    Ann Urol (Paris); 1998; 32(2):69-72. PubMed ID: 9599634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiparametric MRI for prostate cancer screening].
    Hoeks CM; Fütterer JJ; Somford DM; van Oort IM; Huisman H; Barentsz JO
    Ned Tijdschr Geneeskd; 2009; 153():B487. PubMed ID: 20003566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.
    Karazanashvili G; Abrahamsson PA
    J Urol; 2003 Feb; 169(2):445-57. PubMed ID: 12544286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.